医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Ph.D

Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: as Chief Development Officer Overland Pharmaceuticals Appoints Roger Luo Ph.D

2021年08月02日

EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer

EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: as Chief Technology Officer EpimAb Biotherapeutics Appoints Jerry Su Ph.D

2021年05月27日

LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer

LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: as Chief Executive Officer LianBio Appoints Yizhe Wang Ph.D

2021年05月10日

BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Appoints Corsee Sanders Ph.D

2020年08月25日

Terns Pharmaceuticals Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, Ph.D., as Chief Financial Officer, and Erin Quirk, M.D., as President

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and Erin Quirk as Chief Financial Officer Mark Vignola Ph.D Terns Pharmaceuticals Appoints Senthil Sundaram as Chief Executive Officer

2020年08月10日

EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer to Drive Corporate Development Plans

EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer to Drive Corporate Development Plans

バイオテクノロジーヘルスケア製薬　 TimeLine: EpimAb Biotherapeutics Appoints David Gu Ph.D

2020年03月24日

Terns Pharmaceuticals Announces the Addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan Shih, Ph.D., as Scientific Advisors

Terns Pharmaceuticals Announces the Addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan Shih, Ph.D., as Scientific Advisors

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: and Chuan Shih as Scientific Advisors Lopez-Talavera Ph.D Terns Pharmaceuticals Announces the Addition

2018年04月13日

Terns Pharmaceuticals和上海拓臻生物科技有限公司宣布由Juan Carlos Lopez-Talavera, M.D., Ph.D. 与Chuan Shih, Ph.D.担任科学顾问

Terns Pharmaceuticals和上海拓臻生物科技有限公司宣布由Juan Carlos Lopez-Talavera, M.D., Ph.D. 与Chuan Shih, Ph.D.担任科学顾问

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Ph.D Terns Pharmaceuticals和上海拓臻生物与Chuan Shih

2018年04月13日